Brooks Michael, Mo Qianxing, Krasnow Ross, Ho Philip Levy, Lee Yu-Cheng, Xiao Jing, Kurtova Antonina, Lerner Seth, Godoy Gui, Jian Weiguo, Castro Patricia, Chen Fengju, Rowley David, Ittmann Michael, Chan Keith Syson
Scott Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA.
Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA.
Oncotarget. 2016 Dec 13;7(50):82609-82619. doi: 10.18632/oncotarget.12089.
Non-muscle invasive bladder cancers (NMIBC) are generally curable, while ~15% progresses into muscle-invasive cancer with poor prognosis. While efforts have been made to identify genetic alternations associated with progression, the extracellular matrix (ECM) microenvironment remains largely unexplored. Type I collagen is a major component of the bladder ECM, and can be altered during cancer progression. We set out to explore the association of type I collagen with NMIBC progression.
The associations of COL1A1 and COL1A2 mRNA levels with progression were evaluated in a multi-center cohort of 189 patients with NMIBCs. Type I collagen protein expression and structure were evaluated in an independent single-center cohort of 80 patients with NMIBCs. Immunohistochemical analysis was performed and state-of-the-art multi-photon microscopy was used to evaluate collagen structure via second harmonic generation imaging. Progression to muscle invasion was the primary outcome. Kaplan-Meier method, Cox regression, and Wilcoxon rank-sum were used for statistical analysis.
There is a significant association of high COL1A1 and COL1A2 mRNA expression in patients with poor progression-free survival (P=0.0037 and P=0.011, respectively) and overall survival (P=0.024 and P=0.012, respectively). Additionally, immunohistochemistry analysis of type I collagen protein deposition revealed a significant association with progression (P=0.0145); Second-harmonic generation imaging revealed a significant lower collagen fiber curvature ratio in patients with invasive progression (P = 0.0018).
Alterations in the ECM microenvironment, particularly type I collagen, likely contributes to bladder cancer progression. These findings will open avenues to future functional studies to investigate ECM-tumor interaction as a potential therapeutic intervention to treat NMIBCs.
非肌层浸润性膀胱癌(NMIBC)通常是可治愈的,而约15%会进展为预后不良的肌层浸润性癌。尽管已努力识别与进展相关的基因改变,但细胞外基质(ECM)微环境在很大程度上仍未得到充分探索。I型胶原蛋白是膀胱ECM的主要成分,在癌症进展过程中可能会发生改变。我们着手探索I型胶原蛋白与NMIBC进展之间的关联。
在一个由189例NMIBC患者组成的多中心队列中评估COL1A1和COL1A2 mRNA水平与进展的关联。在一个由80例NMIBC患者组成的独立单中心队列中评估I型胶原蛋白的蛋白表达和结构。进行免疫组织化学分析,并使用先进的多光子显微镜通过二次谐波产生成像来评估胶原蛋白结构。进展为肌层浸润是主要结局。采用Kaplan-Meier法、Cox回归和Wilcoxon秩和检验进行统计分析。
高COL1A1和COL1A2 mRNA表达与无进展生存期较差的患者(分别为P = 0.0037和P = 0.011)以及总生存期较差的患者(分别为P = 0.024和P = 0.012)存在显著关联。此外,I型胶原蛋白蛋白沉积的免疫组织化学分析显示与进展存在显著关联(P = 0.0145);二次谐波产生成像显示浸润性进展患者的胶原纤维曲率比显著更低(P = 0.0018)。
ECM微环境的改变,尤其是I型胶原蛋白的改变,可能促成膀胱癌的进展。这些发现将为未来的功能研究开辟途径,以研究ECM-肿瘤相互作用作为治疗NMIBC的潜在治疗干预措施。